Cost-Effectiveness of Fruquintinib for Refractory Metastatic Colorectal Cancer in the USA
Despite the survival benefit, fruquintinib was not cost-effective compared with the placebo in patients with refractory metastatic colorectal cancer in the US setting, on the basis of the conventional willingness-to-pay threshold. Our findings may provide a basis for informing the pricing and reimbursement decisions regarding fruquintinib.
Authors
- Shouhao Zhou (ORCID: https://orcid.org/0000-0002-8124-5047)
- Dong-Won Kang (ORCID: https://orcid.org/0000-0002-7088-867X)
- Patricio B. Lynn (ORCID: https://orcid.org/0000-0002-1004-6032)
- Chan Shen (ORCID: https://orcid.org/0000-0001-5463-3872)
- Li Wang (ORCID: https://orcid.org/0000-0002-0496-9500)
Institutions
- Pennsylvania State University (US)
- Department of Public Health (MM)
Publication Details
- Journal
- PharmacoEconomics - Open
- Published
- 2024-10-08
- DOI
- https://doi.org/10.1007/s41669-024-00529-z
- Citations
- 2
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.57